Poseida Therapeutics, Inc. (PSTX)
| Market Cap | 293.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -162.59M |
| Shares Out | 62.51M |
| EPS (ttm) | -2.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 230,341 |
| Open | 4.75 |
| Previous Close | 4.82 |
| Day's Range | 4.59 - 4.82 |
| 52-Week Range | 4.59 - 13.64 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 27.67 (+488.7%) |
| Earnings Date | n/a |
About PSTX
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat rel...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for PSTX stock is "Strong Buy." The 12-month stock price forecast is 27.67, which is an increase of 488.72% from the latest price.
News
Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current Pre...
SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allog...
SAN DIEGO, Dec. 20, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...
Poseida Therapeutics, Inc. (PSTX) Moves to Buy: Rationale Behind the Upgrade
Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematolog...
SAN DIEGO , Dec. 13, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ...
Wall Street Analysts Think Poseida Therapeutics, Inc. (PSTX) Could Surge 277%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 276.7% in Poseida Therapeutics, Inc. (PSTX). While the effectiveness of this highly sought-after metric is questi...
Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021
SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...
Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Societ...
SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...
Wall Street Analysts Predict a 281% Upside in Poseida Therapeutics, Inc. (PSTX): Here's What You Should Know
The mean of analysts' price targets for Poseida Therapeutics, Inc. (PSTX) points to a 281% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen...
Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences
SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...
Poseida Therapeutics Announces Leadership Appointments
SAN DIEGO, Oct. 13, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...
A new deal with Takeda could mean up to $3.6 billion in milestone payments for Poseida Therapeutics
Shares of Poseida Therapeutics Inc. PSTX, +1.22% were up 9.6% in premarket trading on Tuesday after the company said it signed a research and licensing agreement with Takeda Pharmaceutical Co. Ltd. 4502...
Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies
SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...
Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting
SAN DIEGO, Oct. 1, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...
Poseida's Solid Tumor CAR-T Candidate Data Fails To Impress Investors
The death of a patient in a solid tumor trial hit Poseida Therapeutics Inc (NASDAQ: PSTX) hard last August, but since then, the hold has been lifted, and it is now reporting some early data from that sa...
Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit
SAN DIEGO, Aug. 31, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...
Poseida's Fully Allogeneic CAR-T Product Enters Human Trial For Multiple Myeloma
The FDA has cleared Poseida Therapeutics Inc (NASDAQ: PSTX) Investigational New Drug (IND) application for P-BCMA-ALLO1, a fully allogeneic CAR-T product candidate for relapsed/refractory multiple myelo...
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic ...
SAN DIEGO, Aug. 30, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...
New Strong Sell Stocks for August 27th
CDLX, UUUU, IVC, PSTX, and CYTK have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2021
Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021
SAN DIEGO, Aug. 12, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...
Poseida Therapeutics Appoints Cynthia Collins to Board of Directors
SAN DIEGO, July 26, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...
Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders
SAN DIEGO, June 2, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...
Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021
SAN DIEGO, May 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...
Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American...
SAN DIEGO, May 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...
Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board
SAN DIEGO, May 6, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...
Poseida Therapeutics to Present at BofA Securities 2021 Virtual Health Care Conference
SAN DIEGO, May 5, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cel...